ArticleCureus2026
Same-Day Discharge After GreenLight Laser Photoselective Vaporization of the Prostate in Patients With Moderate to Severe Lower Urinary Tract Symptoms.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe most common cause of severe lower urinary tract symptoms (LUTS) in men over 50 is benign prostatic hyperplasia (BPH). A wide range of day-case surgical options are practiced, among which GreenLight Photoselective Vaporization of the Prostate (GL-PVP) is one. This has completely taken over conventional bipolar transurethral resection of the prostate (TURP). There is a need to study whether in patients with moderate and severe International Prostate Symptom Score (IPSS) scores, GL-PVP can give safe and effective outcomes as a same-day discharge (SDD). Objective: To study the safety and effectiveness of GL-PVP as SDD in patients with moderate and severe LUTS. Method: The study was conducted at King's College Hospital, United Kingdom (UK). Patients presenting with severe LUTS on IPSS and quality of life (QOL) scoring were included. All patients had their pre-operative IPSS + QOL scoring and flow rate measured by uroflowmetry in the clinic. They underwent GL-PVP and were discharged on the same day safely. Following this post-op, IPSS and flow rate on uroflowmetry were measured in the first follow-up. Results: A total of 103 patients were included in the study, with prostate size ranging from 30 cc to 124 cc. The average laser time during GL-PVP was 21 mins, with an average energy used of 131,154 J. The mean improvement in IPSS + QOL score was from 25 ± 4 to 11.89 ± 1.61. The mean improvement in Q-max was from 9.81 ml/sec to 15.11 ml/sec. The mean improvement in post-void residual (PVR) volume was from 266 ml to 74.19 ml. None of the patients required secondary admissions or second procedures. Conclusion: There was a marked improvement in IPSS + QOL scoring along with flow rate and PVR after SDD from GL-PVP prostate, proving efficacy and safety. This can be the alternative surgical option for patients with severe LUTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.